"Asthma Paradoxes"
Dr Hao-Chien Wang responds:
FeNO is a marker of eosinophilic inflammation & TH2 inflammation of airway. It could be used as a composite marker when we try to consider using biologics, another clinical application is to monitor the patient’s compliance of ICS.
Dr Hao-Chien Wang responds:
Considering over use (over reliance) of SABA, the most important thing is patient education: We should emphasize the importance of controller usage (for better symptom control, improved asthma related clinical outcomes, less healthcare resource utilization) and the risk of SABA overuse (poor asthma control, risk of acute exacerbation & increased mortality). Another strategy is try to use formoterol/ICS (anti-inflammatory reliever) for these patients (SMART approach).
Dr Hao-Chien Wang responds:
Leukotriene modifier (Montelukast) has some role in asthma treatment:
Dr Duminda Yasaratne responds:
usually at mid-second week. There were another few who developed symptoms close to term. Thanks.